Olipudase alfa (acid sphingomyelinase deficiency (ASMD) type A/B or type B)



  • Active Substance: Olipudase alfa
  • Name: Xenpozyme®
  • Therapeutic area: Acid sphingomyelinase deficiency (ASMD)
  • Pharmaceutical company: Sanofi-Aventis Deutschland GmbH


Time table:

  • Start: 01.10.2022
  • Publication of assessment: 02.01.2023
  • End of public hearing: 23.01.2023
  • Final decision by G-BA: middle of March 2023


Comparative therapy:

  • No comparative therapy due to orphan drug designation